SCHEMBL4628708

SCHEMBL4628708

Cc1ccccc1C(=O)NC(=N)Nc1ccccc1C(C)C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
KDM4E B2RXH2 2/20 0.48
POLB P06746 1/20 0.48
ALOX12 P18054 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 4/20 0.45
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
MEN1 O00255 2/20 0.43
NLRP3 Q96P20 1/20 0.43
CFTR P13569 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KCNK3 O14649 1/20 0.42
KCNK9 Q9NPC2 1/20 0.42
AKR1C3 P42330 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25872079 0.86 LMNA (0.58) ALDH1A1KDM4EMAPTLMNAGAA
SCHEMBL4628954 0.82 LMNA (0.55) POLBKMT2AMAPTLMNAGAA
SCHEMBL4628744 0.81 SCN5A (0.53) ALDH1A1KDM4EALOX12KMT2AMAPT
SCHEMBL2503451 0.79 HPGD (0.56) ALDH1A1KDM4EPOLBALOX12KMT2A
SCHEMBL4629385 0.78 SMN1; SMN2 (0.51) ALDH1A1ALOX12KMT2AMAPTLMNA
SCHEMBL4629400 0.77 MAPT (0.45) ALDH1A1KMT2AMAPTLMNAAKR1C3
SCHEMBL30479702 0.77 GRIN2D (0.53) POLBKMT2AMAPTNLRP3L3MBTL1
SCHEMBL6721277 0.77 GRIN2D (0.53) POLBKMT2AMAPTNLRP3L3MBTL1
SCHEMBL28642674 0.74 LMNA (0.52) ALDH1A1KDM4EMAPTLMNAGAA
SCHEMBL4628567 0.74 KMT2A (0.53) ALDH1A1KDM4EPOLBALOX12KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA ALDH1A1 858/4885KDM4E 3300/4885POLB 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.